Physician profile
Monte Dale Moore
NPI 1558829382
$3,443.26
in general payments reported to CMS, 2019-2025
18 companies · $670 in 2025
The $670 reported for 2025 was more than what 81% of Psychiatric/Mental Health, Child & Family providers received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $525 · 2023: $956 · 2024: $971 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.45 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,392.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $493.07 | 2023-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $473.24 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $270.71 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $269.27 | 2021-2022 | |
| Tris Pharma INC | $97.83 | 2023-2024 | Dyanavel Xr, Quillivant |
| Corium, LLC | $91.56 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $83.78 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $57.17 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $44.67 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.17 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $39.56 | 2021-2023 | Bridion |
| Vertex Pharmaceuticals Incorporated | $16.67 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.46 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $15.82 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.00 | 2022 | |
| Sanofi Pasteur INC. | $13.64 | 2022 | |
| Indivior INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.